Nebcina (Tobramycin)

Tobramycin, the active ingredient in Nebcina, is a aminoglycoside antibiotic presented as an injectable solution for intramuscular and intravenous use. It treats serious gram‑negative bacterial infections, including those caused by Pseudomonas aeruginosa, in hospitalised patients. GNH USA supplies Nebcina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Tobramycin is an aminoglycoside antibiotic used to treat serious gram‑negative bacterial infections.

- Serious gram‑negative bacterial infections: provides broad coverage against resistant pathogens. - Pseudomonas aeruginosa infections: offers targeted therapy for respiratory, urinary and wound sites. - Sepsis: used as part of combination regimens to control systemic infection. - Intra‑abdominal infections: helps eradicate mixed aerobic and anaerobic gram‑negative organisms. - Respiratory tract infections: treats severe ventilator‑associated pneumonia. - Urinary tract infections: addresses complicated UTIs caused by resistant gram‑negative bacteria.

Tobramycin may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Nephrotoxicity: elevation of serum creatinine and reduced renal clearance. - Ototoxicity: hearing loss, tinnitus, or balance disturbances. - Neuromuscular blockade: muscle weakness, especially with concurrent neuromuscular blockers. - Vestibular dysfunction: dizziness or vertigo. - Injection site reactions: pain, erythema, or swelling.

Serious or Rare Side Effects: - Anaphylactic reactions: severe allergic response requiring immediate intervention. - Irreversible hearing loss: permanent auditory damage with prolonged exposure. - Severe renal failure: acute kidney injury requiring dialysis. - Respiratory depression: compromised breathing in susceptible patients. - Clostridioides difficile infection: secondary colitis following antibiotic therapy.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

- Renal function monitoring: assess serum creatinine and urine output before and during treatment. - Auditory assessment: perform baseline audiometry and repeat if symptoms of ototoxicity appear. - Concomitant nephrotoxic drugs: avoid or adjust dose when used with vancomycin, amphotericin B, or loop diuretics. - Pregnancy and lactation: use only if potential benefits outweigh known risks. - Elderly patients: consider reduced clearance and adjust dosing accordingly. - Store at ambient temperature: keep in original container, protect from light and moisture.

Tobramycin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other aminoglycosides: additive nephro‑ and ototoxicity. - Loop diuretics (e.g., furosemide): heightened risk of renal impairment. - Neuromuscular blocking agents (e.g., succinylcholine): may cause prolonged paralysis.

Moderate Interactions (Monitor Closely): - Vancomycin: monitor renal function closely when co‑administered. - Amphotericin B: increased potential for kidney injury. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate renal toxicity.